# Algal Oil Triglycerides Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/algal-oil-triglycerides-meta-analysis-evidence-review
Category: evidence-review
Summary: Algal Oil Triglycerides Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are m
Last reviewed: 2026-07-30
Reviewed by: Migaku Evidence Review
# Algal Oil Triglycerides Meta-analysis: What the Evidence Says

## Quick Answer

Algal Oil Triglycerides Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 narrative review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Fish oil supplements in patients with chronic kidney disease | narrative review | 3 | 2026-06-01 | 10.1093/ckj/sfag168 |
| Microalgae Oil Attenuates Liver Fat Deposition in NAFLD via Modulation of Anti‐Lipogenic Genes and Insulin Signaling Pathways in HFD Mice | preclinical study | 4 | 2026-06-14 | 10.1002/fsn3.71882 |

## What The Sources Report

- 1 15 16 15 2 16 17 18 Most of the increased morbidity and mortality associated with CKD is attributable to CVD with an increased risk beginning with both mildly reduced estimated glomerular filtration rate (eGFR) and very low levels of albuminuria (albumin: creatinine ratio >30 mg/g). [Ferro Charles J (2026); evidence level 3]
- This risk increases exponentially and independently with worsening eGFR and albuminuria with the highest risk being observed in individuals with severely reduced eGFR and high levels of albuminuria. [Ferro Charles J (2026); evidence level 3]
- ALT AST DHA GO KEGG LDL-c MSEA NAFLD TBA TC TG 2022 2021 2023 2024 2026 2021 2015 2023 2021 2021 2009 2019 2014 2020 2026 2024 2025 n n n Non-alcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated steatotic liver disease (MASLD) in human pathology, is commonly associated with obesity. [AlQahtani Athba (2026); evidence level 4]
- It is often linked to various health issues, including diabetes, hypertension, kidney diseases, and an increased risk of developing cardiovascular conditions. [AlQahtani Athba (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For algal oil triglycerides meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Ferro Charles J (2026). Fish oil supplements in patients with chronic kidney disease. DOI: 10.1093/ckj/sfag168. PMCID: PMC13261989. PMID: 42293365. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13261989/
- AlQahtani Athba (2026). Microalgae Oil Attenuates Liver Fat Deposition in NAFLD via Modulation of Anti‐Lipogenic Genes and Insulin Signaling Pathways in HFD Mice. DOI: 10.1002/fsn3.71882. PMCID: PMC13265833. PMID: 42305223. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13265833/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.